CORXEL raises up to $287M to Advance Oral GLP-1 and Cardiometabolic Pipeline

Berkeley Heights, NJ, January 22, 2026 (Globe Newswire) -- Corxel Pharmaceuticals closed a Series D1 financing of up to $287 million to accelerate development of its cardiometabolic portfolio, led by the oral small-molecule GLP-1 receptor agonist CX11. The proceeds will fund ongoing U.S. Phase 2 studies in obesity and overweight patients, planned global Phase 2 trials in type 2 diabetes, early Phase 3 preparations, and additional programs spanning acute ischemic stroke and hypertension. The round drew strong participation from leading healthcare investors including RTW Investments, SR One, TCG Crossover, RA Capital, HBM Healthcare Investments, and SymBiosis, and will add three new representatives to CORXEL’s board.

Read full article here.